Xencor Inc Dossier
Qualitative Analysis
Business overview
Xencor, Inc. (NASDAQ: XNCR) is a clinical-stage biopharmaceutical company focused on discovering and developing engineered monoclonal antibodies and other protein therapeutics for the treatment of cancer and autoimmune diseases. The company utilizes its proprietary XmAb® technology platform to engineer the Fc domain of antibodies, enhancing their natural properties and creating novel mechanisms of action. Xencor's business model relies on advancing its internal pipeline of bispecific antibodies and cytokines while leveraging strategic partnerships and licensing agreements with major pharmaceutical companies, which generate milestone payments and royalties.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Xencor is strategically reorienting its pipeline to emphasize wholly owned drug candidates that align with its core protein engineering strengths, such as targeted T cell-engaging bispecific antibodies and dual-targeting bispecifics, while pausing or deprioritizing programs with higher biological uncertainty.
Expected impact: Reduces exposure to biological risks, improves clinical success rates, and focuses resources on high-value oncology and autoimmune assets like XmAb819, XmAb541, XmAb942, and XmAb412.
Leveraging Xencor's proprietary XmAb Fc engineering platform to secure licensing agreements and strategic collaborations with larger pharmaceutical companies, generating upfront payments, milestone achievements, and royalty streams.
Expected impact: Provides non-dilutive funding and validation of the platform technology, complementing internal development capabilities while retaining core asset rights.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Xencor out-licensed exclusive worldwide rights to develop and commercialize obexelimab (an investigational bifunctional antibody targeting CD19 and FcγRIIb) to Zenas BioPharma. This allowed Xencor to offload a stalled asset while retaining significant economic upside through equity ownership and milestone eligibility.
Terms: Xencor received rights to equity in Zenas (holding a significant stake that was valued as a marketable equity security) and is eligible for up to $480 million in potential clinical, regulatory, and commercial milestone payments, plus tiered mid-single digit to mid-teen percent royalties on net sales.